highperformr logo

Abeona Therapeutics's Overview

Total employees155
HeadquartersCleveland
Founded2015

Abeona Therapeutics Inc. is a fully-integrated leader in gene and cell therapy, with a mission to develop and deliver life-changing therapies for people impacted by serious diseases. Their primary focus is on recessive dystrophic epidermolysis bullosa (RDEB) and other rare genetic conditions. Abeona has a portfolio of AAV-based gene therapies and an autologous cell therapy, supported by in-house cGMP manufacturing capabilities. The company is committed to scientific innovation and addressing significant unmet medical needs in the rare disease community.

Where is Abeona Therapeutics's Headquarters?

HQ Function

The Cleveland headquarters serves as the central hub for Abeona's executive leadership, administrative operations, clinical development oversight, research strategy, and business development activities.

Notable Features:

The headquarters is located in a modern office building within Cleveland's Health-Tech Corridor, designed to support the needs of a biopharmaceutical company. The focus is on functional, state-of-the-art office environments that foster innovation.

Work Culture:

Abeona fosters a patient-centric and science-driven work culture. It emphasizes collaboration, innovation, integrity, and a strong commitment to developing transformative therapies for individuals affected by rare diseases.

HQ Significance:

Its Cleveland location provides Abeona with access to a rich talent pool, leading medical research institutions, and a supportive environment for biotechnology companies, crucial for its research and clinical development programs.

Values Reflected in HQ: The headquarters' operations and strategic location reflect Abeona's core values of scientific excellence, a sharp focus on patient needs, unwavering integrity, and a pioneering spirit in gene and cell therapy development.

Location:

While Abeona Therapeutics' core operations, including its headquarters and cGMP manufacturing, are based in the United States (Cleveland, Ohio), its impact is global. The company conducts clinical trials that may involve international sites to reach diverse patient populations for rare diseases. Furthermore, Abeona has entered into strategic collaborations, such as the licensing agreement with Chiesi Global Rare Diseases for the commercialization of EB-101 (Pz-cel™) in Europe and other select markets, extending its therapeutic reach internationally pending regulatory approvals.

Street Address:

6555 Carnegie Ave, Suite 410

City:

Cleveland

State/Province:

Ohio

Country:

USA

Abeona Therapeutics's Global Presence

Cleveland, Ohio/USA

Address: Cleveland, Ohio (Specific street address for the cGMP facility is not consistently publicized for general public, but it is a distinct site from the corporate HQ)

The Cleveland-based GMP facility is integral to Abeona's research, development, and future commercialization efforts, enabling in-house manufacturing, quality control, and process development for its advanced therapy candidates. This ensures control over the supply chain for its specialized treatments.

Buying Intent Signals for Abeona Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Abeona Therapeutics

As of April 2025, Abeona Therapeutics' leadership includes:

Vishwas Seshadri, Ph.D., M.B.A. - President & Chief Executive Officer
Joseph Vazzano - Chief Financial Officer
Brian Pereira, M.D. - Head of R&D and Chief Medical Officer
Madhav Vasanth, Ph.D., M.B.A. - Chief Technical Officer
Brendan M. O’Malley, J.D., Ph.D. - General Counsel & Corporate Secretary

Investors of Abeona Therapeutics

Abeona Therapeutics has been backed by several prominent investors over the years, including:

Adage Capital Management, L.P.
BlackRock Inc.
The Vanguard Group, Inc.
Suvretta Capital Management, LLC
Point72 Asset Management, L.P.
Knoll Capital Management
Deerfield Management

Executive New Hires/Exits in the Last 12 Months

Hire4
Exits2

Over the past 12-18 months, Abeona Therapeutics has significantly reshaped its executive leadership team. This includes the appointment of a permanent CEO (previously interim), a new CFO, a new CTO, and a new Head of R&D and CMO. These changes occurred alongside departures of the former CEO and CFO, reflecting a period of strategic transition and team building for the company's next phase of growth and potential commercialization.

Departures

Michael Amoroso, Michael Amoroso resigned as President and CEO.
Edward Carr, Edward Carr departed as Chief Financial Officer.

New Appointments:

Madhav Vasanth, Ph.D., M.B.A., Madhav Vasanth appointed as Chief Technical Officer.
Vishwas Seshadri, Ph.D., M.B.A., Vishwas Seshadri appointed permanent President & CEO (formerly interim).
Joseph Vazzano, Joseph Vazzano appointed as Chief Financial Officer.
Brian Pereira, M.D., Brian Pereira appointed as Head of R&D and Chief Medical Officer.

Technology (Tech Stack) used by Abeona Therapeutics

Discover the tools Abeona Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Abeona Therapeutics Email Formats and Examples

Abeona Therapeutics commonly uses a standard corporate email format. The most frequently observed pattern is the first initial of the employee's first name followed by their last name, all before the '@' symbol and the company domain.

[first_initial][last]@abeonatherapeutics.com

Format

vseshadri@abeonatherapeutics.com

Example

80%

Success rate

News and media

Abeona Therapeutics / GlobeNewswireMay 24, 2024

Abeona Therapeutics Announces FDA Approval of Pz-cel™ (beremagene geperpavec) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Abeona Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved Pz-cel™ (beremagene geperpavec), its autologous, COL7A1 gene-corrected epidermal sheets, for treating wounds in patients six months or older with Recessive Dystrophic Epidermolysis Bullosa. This is a landmark approval for the RDEB community....more

Abeona Therapeutics / GlobeNewswireMay 10, 2024

Abeona Therapeutics Reports First Quarter 2024 Financial Results and Provides Update on EB-101 Biologics License Application

Abeona Therapeutics provided its Q1 2024 financial results and an update on its Biologics License Application (BLA) for EB-101 (Pz-cel™), noting its preparedness for the PDUFA target action date of May 25, 2024, and potential commercial launch. The company discussed its financial position and ongoing programs....more

Abeona Therapeutics / GlobeNewswireSeptember 26, 2023

Abeona Therapeutics Enters into an Exclusive License Agreement with Chiesi Global Rare Diseases for Commercialization of EB-101 in Europe and Other Select Markets

Abeona Therapeutics announced an exclusive license agreement with Chiesi Global Rare Diseases to commercialize EB-101 (Pz-cel™) for RDEB in the European Union, U.K., Switzerland, and other specified markets. Abeona received an upfront payment and is eligible for further milestone payments and royalties....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Abeona Therapeutics, are just a search away.